Jacobio Pharma (1167.HK) has reason to celebrate as its clinical-stage oncology solutions have been selected for presentation at the 2023 European Society for Medical Oncology (ESMO) Congress.
The Proffered Paper presentation will showcase the company’s unique approach to tackling undruggable targets in oncology. This recognition is a great leap forward for Jacobio Pharma and marks an important milestone on its journey to delivering innovative healthcare solutions.
The power of combination therapy is about to be revealed in a new clinical trial examining the effects of Glecirasib, a KRAS G12C inhibitor, in combination with JAB-3312, a SHP2 inhibitor, on patients with KRAS p.G12C mutated solid tumors. This trail promises to uncover the potential of these treatments in providing a new hope for those facing these formidable cancers.
We are thrilled to be given the chance to present our data at 2023 ESMO Congress, as we are confident that our results will greatly assist in furthering the development of SHP2 inhibitors as a viable treatment for solid tumors in cancer patients.
We would like to express our profound gratitude to the patients and investigators who were involved in this critical study. At Jacobio, we remain dedicated to pushing for the growth of SHP2-centric therapeutic plans to aid those battling cancer.
At the 2022 ESMO Asia Congress, Jacobio presented pre-clinical results of the SHP2 inhibitor and KRAS G12C inhibitor combination, showing that this synergistic duo efficiently inhibited tumor growth in multiple KRAS G12C tolerant models. This is a remarkable discovery that could potentially overcome resistance to KRAS G12C inhibitor therapies in non-small cell lung cancer (NSCLC) patients.
Glecirasib, a KRAS G12C inhibitor developed by Jacobio, is undergoing clinical trials in China, the United States and Europe for patients with advanced solid tumors harboring the KRAS G12C mutation. The pivotal trial in China is aimed at NSCLC, while the monotherapy study for STK11 co-mutated NSCLC is taking place in the front-line setting.
Combination therapy trials are also being conducted with the SHP2 inhibitor JAB-3312 in NSCLC, and Cetuximab in colorectal cancer, making glecirasib an exciting and promising opportunity to improve the outlook of those with advanced solid tumors.
Jacobio is pioneering the clinical use of JAB-3312, an allosteric SHP2 inhibitor with unprecedented potential. In groundbreaking trials across China, Europe and the United States, JAB-3312 is being studied both as a monotherapy and in combination with Glecirasib and other treatments, paving the way for a revolutionary approach to patient care.
Jacobia Pharma (1167.HK) is on a mission to challenge the status quo and revolutionize healthcare. We are focused on novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, p53, RB and MYC, using our Induced Allosteric Drug Discovery (IADDP) and iADC Platforms.
Our aim is to become a leading player in R&D and herald a new revolution in this field. We proudly call Beijing, Shanghai and Boston our research and development hubs. Our commitment is to lead from the front and create wonders that improve people’s health.